Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma
Authors:
- Daniel MillsDMDaniel Mills
- Michael PotterMPMichael Potter
- Steven BollipoSBSteven Bollipo
- Liam ShunLSLiam Shun
- Jaw TronidjajaJTJaw Tronidjaja
- Swetha SridharanSSSwetha Sridharan
- Mahesh KumarMKMahesh Kumar
- Jarad MartinJMJarad Martin
- Yuvnik TradaYTYuvnik Trada
Open Access
- 1 April 2026
- journal article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (2) , 78
Abstract
Background: Hepatocellular carcinoma (HCC) often develops in the setting of chronic liver disease, making preservation of hepatic function central to treatment decisions. Despite this, the temporal change on liver function caused by stereotactic body radiation therapy (SBRT), particularly using objective measures such as the albumin–bilirubin (ALBI) score, remains poorly defined. This retrospective study aimed to measure temporal changes in liver function in patients with HCC treated with SBRT. Comparable data was also obtained from patients treated with microwave ablation (MWA), a liver-directed therapy with negligible impact on hepatic function, acting as a control cohort for estimating changes attributable to underlying cirrhosis rather than treatment. Methods: A total of 126 patients with HCC were included, 72 in the SBRT and 54 in the control cohorts respectively. Biochemical data was extracted before and at 3, 6 and 12 months post-treatment for calculation of albumin-bilirubin (ALBI) and Child-Pugh (CP) scores. Clinical and dosimetric data was obtained for assessment of factors associated with change in liver function following SBRT. Results: Baseline liver function was similar between the SBRT and control cohorts (ALBI score, −2.30 vs. −2.27, P=0.68). The median lesion size was significantly larger in the SBRT group (37 vs. 20 mm, PConclusions: Liver function as measured by ALBI score gradually declines following SBRT for HCC, with larger lesion size associated with greater change. However, this change is only significant in a minority of our cohort with added contributions from non-treatment-related factors including co-existing cirrhosis.Keywords
This publication has 33 references indexed in Scilit:
- Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patientsWorld Journal of Gastroenterology, 2017
- Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinomaActa Oncologica, 2016
- Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapyPractical Radiation Oncology, 2015
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinomaRadiation Oncology, 2014
- Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinomaRadiation Oncology, 2013
- Stereotactic Body Radiotherapy for Primary Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinomaClinical and Translational Oncology, 2010
- Assessment of Prognosis of CirrhosisSeminars in Liver Disease, 2008
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004